# Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer

> **NCT05041842** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **UNICANCER** · enrollment: 53 (actual)

## Conditions studied

- Metastatic Breast Cancer With a Isolated Brain Progression

## Interventions

- **DRUG:** Tucatinib
- **DRUG:** Pertuzumab
- **DRUG:** Trastuzumab
- **DRUG:** Hormone therapy
- **DRUG:** Pertuzumab/ Trastuzumab

## Key facts

- **NCT ID:** NCT05041842
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-17
- **Primary completion:** 2025-04-30
- **Final completion:** 2026-04-30
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2025-11-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05041842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05041842, "Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05041842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*